Regen BioPharma (Regen BioPharma) EV-to-EBIT : -4.05 (As of May. 06, 2024)

Regen BioPharma EV-to-EBIT Chart

Regen BioPharma Annual Data
	Trend	Sep14	Sep15	Sep16	Sep17	Sep18	Sep19	Sep20	Sep21	Sep22	Sep23
EV-to-EBIT		Get a 7-Day Free Trial					-3.08	0.72	-21.15	12.81	5.73

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															0.10	4.75	5.73	-5.43	-4.50

Competitive Comparison of Regen BioPharma's EV-to-EBIT

For the Biotechnology subindustry, Regen BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's EV-to-EBIT falls into.

Regen BioPharma EV-to-EBIT Calculation

Regen BioPharma's EV-to-EBIT for today is calculated as:

Regen BioPharma's current Enterprise Value is $3.33 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma  (OTCPK:RGBP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Regen BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Regen BioPharma's Enterprise Value for the quarter that ended in Mar. 2024 was $3.70 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description